Yu Cao

Yu Cao has a diverse work experience in the field of biotechnology and oncology research. They began their career as a Postdoctoral Researcher at Augusta University, where they studied the mechanisms of T cell dysfunction in the tumor microenvironment and drug resistance in hepatocellular carcinoma. Following this, they worked as a Research Scientist at the Moffitt Cancer Center, where they focused on designing novel T cell therapies for solid tumors and investigating the role of Chop in CD8+ T cell function.

Yu then joined Agios Pharmaceuticals as a Scientist, where they served as the biology lead for immune-oncology projects. They were involved in target discovery, biomarker identification, and drugging strategy exploration for immuno-oncology therapies. After Agios Pharmaceuticals was acquired by Servier, Yu continued to work in the same team, contributing to the development of therapies for turning "cold" tumors "hot" and enhancing the efficacy of immune checkpoint inhibitors.

Currently, Yu is employed at Tessera Therapeutics as a Senior Scientist and Principal Scientist. They are responsible for leading preclinical translational work and serving as a principal investigator for various projects related to gene writing and re-writing modalities, delivery systems, and gene and cell therapies.

Overall, Yu Cao's work experience demonstrates their expertise in translational research, immunotherapy, and developing novel therapeutic approaches for oncology.

Yu Cao's education history includes a Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology from the Academy of Military Sciences, a Master of Science (MS) in Infection and Immunity from the University of Sydney, and a Bachelor of Science (BS) in Biotechnology from Sichuan University. Additionally, Yu Cao has obtained several certifications including "Leading Yourself," "Leading at a Distance," "Management Foundations," and "Take a More Creative Approach to Problem-Solving" from LinkedIn.